LY450108 is primarily investigated for its potential therapeutic applications in the treatment of Alzheimer's disease. It functions as a gamma-secretase inhibitor, targeting the enzyme involved in the production of amyloid-beta peptides, which are implicated in the formation of amyloid plaques in the brain. By inhibiting this enzyme, LY450108 aims to reduce amyloid plaque buildup, potentially slowing disease progression. Clinical studies have explored its efficacy and safety in patients with mild to moderate Alzheimer's, though further research is needed to confirm its long-term benefits and tolerability. Its development represents a significant effort in addressing the underlying pathology of Alzheimer's disease.